ArticleJournal of inflammation research2025
Association of TIMP-2 Expression with Postoperative Prognosis in Hepatocellular Carcinoma Patients and Development of a Predictive Model.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the expression of tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in postoperative patients with hepatocellular carcinoma (HCC), its relationship with prognosis, and to build a nomogram prediction model for overall survival (OS) and disease-free survival (DFS) based on TIMP-2 expression. Patients and Methods: Expression profile data from HCC-related datasets were obtained from the Gene Expression Omnibus to analyze the correlation between TIMP-2 and HCC survival and prognosis, and its relationship with the HCC tumor immune microenvironment. Overall, 118 patients who underwent radical surgery for HCC were included retrospectively. To investigate the relationship between TIMP-2 expression and the clinicopathological characteristics and prognosis of patients with HCC, Cox regression analysis was used to determine the independent prognostic factors for DFS and OS. A nomogram prediction model for OS and DFS after HCC was established based on TIMP-2. Results: In the TIMP-2 high expression group, CD4+ T cells, CD8+ T lymphocytes, macrophages, and natural killer cells were the predominant infiltrates. The 1-, 2-, 3-, and 5-year survival and DFS rates in the low TIMP-2 expression group were higher than in the high TIMP-2 expression group ( Conclusion: TIMP-2 may be involved in regulating the immune microenvironment as an immune inflammation-related gene in HCC. The nomogram prediction model of OS and DFS after HCC was established based on TIMP-2, providing a tool to predict the survival prognosis and recurrence risk of patients after HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.